{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T20:11:31Z","timestamp":1789935091601,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100016110","name":"Taizhou University","doi-asserted-by":"publisher","award":["L2023FSXY15"],"award-info":[{"award-number":["L2023FSXY15"]}],"id":[{"id":"10.13039\/501100016110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LBY23H200004"],"award-info":[{"award-number":["LBY23H200004"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.19080"],"award-info":[{"award-number":["320.6750.19080"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.colsurfb.2026.116154","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:01:46Z","timestamp":1789052506000},"page":"116154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CXCR4-directed liposomal co-delivery of cytarabine and AMD3100 for redox-associated chemosensitization in acute myeloid leukemia"],"prefix":"10.1016","volume":"269","author":[{"given":"Wenwen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunyi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-7724","authenticated-orcid":false,"given":"Linglong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.colsurfb.2026.116154_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.116154_bib2","doi-asserted-by":"crossref","first-page":"9189","DOI":"10.1038\/s41467-024-53629-z","article-title":"Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis","volume":"15","author":"Culver-Cochran","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.colsurfb.2026.116154_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176013","article-title":"Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery","volume":"958","author":"Davodabadi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.116154_bib4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.colsurfb.2026.116154_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105090","article-title":"The role of the bone marrow microenvironment in leukemic stem cell resistance: Pathways of persistence and selection","volume":"218","author":"Barachini","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"10.1016\/j.colsurfb.2026.116154_bib6","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2008.238","article-title":"The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation","volume":"22","author":"Tavor","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.colsurfb.2026.116154_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116605","article-title":"Discovery of novel CXCR4 inhibitors for the treatment of inflammation by virtual screening and biological evaluation","volume":"275","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.colsurfb.2026.116154_bib8","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1172\/JCI66553","article-title":"CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia","volume":"123","author":"Chen","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.colsurfb.2026.116154_bib9","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1038\/bcj.2017.21","article-title":"A phase 1\/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia","volume":"7","author":"Uy","year":"2017","journal-title":"Blood Cancer J."},{"issue":"24","key":"10.1016\/j.colsurfb.2026.116154_bib10","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1182\/blood-2008-06-162123","article-title":"Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100","volume":"113","author":"Nervi","year":"2009","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.colsurfb.2026.116154_bib11","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","article-title":"Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML","volume":"113","author":"Zeng","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.colsurfb.2026.116154_bib12","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/s41375-024-02326-3","article-title":"CXCR4 as a therapeutic target in acute myeloid leukemia","volume":"38","author":"Korbecki","year":"2024","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.colsurfb.2026.116154_bib13","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.leukres.2007.02.017","article-title":"Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells","volume":"31","author":"Liesveld","year":"2007","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.colsurfb.2026.116154_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jss.2008.06.044","article-title":"A CXCR4 Antagonist CTCE-9908 Inhibits Primary Tumor Growth and Metastasis of Breast Cancer1","volume":"155","author":"Huang","year":"2009","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.colsurfb.2026.116154_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103958","article-title":"Redox-dependent protein S-glutathionylation governs azacitidine sensitivity and resistance in AML","volume":"89","author":"Nemes","year":"2026","journal-title":"Redox Biol."},{"issue":"3","key":"10.1016\/j.colsurfb.2026.116154_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ccr.2006.08.009","article-title":"Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by \u03b2-phenylethyl isothiocyanate","volume":"10","author":"Trachootham","year":"2006","journal-title":"Cancer Cell."},{"issue":"17","key":"10.1016\/j.colsurfb.2026.116154_bib17","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia","volume":"119","author":"Uy","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.116154_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2011.197","article-title":"Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4","volume":"26","author":"Rettig","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.116154_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41392-026-02583-x","article-title":"Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications","volume":"11","author":"Akter","year":"2026","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.colsurfb.2026.116154_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2019.06.033","article-title":"Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma","volume":"307","author":"Lakkadwala","year":"2019","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.colsurfb.2026.116154_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10147-014-0740-0","article-title":"CXCR4 promotes GSK3\u03b2 expression in pancreatic cancer cells via the Akt pathway","volume":"20","author":"Ma","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.colsurfb.2026.116154_bib22","doi-asserted-by":"crossref","first-page":"e0177227","DOI":"10.1371\/journal.pone.0177227","article-title":"Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2","volume":"12","author":"Karathedath","year":"2017","journal-title":"PLoS. One"},{"key":"10.1016\/j.colsurfb.2026.116154_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114040","article-title":"Liposomal dexamethasone for intra-articular therapy: Functional strategies and clinical progress","volume":"385","author":"Yao","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2026.116154_bib24","article-title":"A biomimetic liposome platform targeting non-small cell lung cancer to modulate the inflammatory and metabolic microenvironment for enhanced therapy","author":"Jiang","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.colsurfb.2026.116154_bib25","first-page":"15","article-title":"Resetting amino acid metabolism of cancer cells by ATB(0,+)-targeted nanoparticles for enhanced anticancer therapy","volume":"9","author":"Kou","year":"2022","journal-title":"Bioact. Mater."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.116154_bib26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41181-024-00282-y","article-title":"Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma","volume":"9","author":"Waked","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"10","key":"10.1016\/j.colsurfb.2026.116154_bib27","doi-asserted-by":"crossref","first-page":"7945","DOI":"10.1007\/s00432-022-04444-w","article-title":"CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment","volume":"149","author":"Bao","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.colsurfb.2026.116154_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1060537","article-title":"Molecular and epigenetic alterations in normal and malignant myelopoiesis in human leukemia 60 (HL60) promyelocytic cell line model","volume":"11","author":"Basu","year":"2023","journal-title":"Front. Cell. Dev. Biol."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.116154_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40364-026-00915-1","article-title":"The molecular landscape of the C1498 murine acute myeloid leukemia cell line","volume":"14","author":"Ghetti","year":"2026","journal-title":"Biomark. Res."},{"issue":"17","key":"10.1016\/j.colsurfb.2026.116154_bib30","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia","volume":"119","author":"Uy","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.colsurfb.2026.116154_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26414","volume":"64","author":"Cooper","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"issue":"14","key":"10.1016\/j.colsurfb.2026.116154_bib32","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/bloodadvances.2019000098","article-title":"Dual-action CXCR4-targeting liposomes in leukemia: function blocking and drug delivery","volume":"3","author":"McCallion","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.116154_bib33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41417-019-0095-9","article-title":"Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia","volume":"27","author":"Wang","year":"2020","journal-title":"Cancer Gene Ther."},{"issue":"3","key":"10.1016\/j.colsurfb.2026.116154_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030727","article-title":"T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo","volume":"15","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2026.116154_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2026.115574","article-title":"Multifunctional liposomes for staged osteoarthritis therapy: From symptom management to regeneration","volume":"263","author":"Yao","year":"2026","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2026.116154_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtbio.2024.101279","article-title":"Enhancing retention and permeation of rapamycin for osteoarthritis therapy using a two-stage drug delivery system","author":"Lin","year":"2024","journal-title":"Mater. Today Bio"},{"issue":"10","key":"10.1016\/j.colsurfb.2026.116154_bib37","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.3390\/cancers12102837","article-title":"Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery","volume":"12","author":"Kou","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.116154_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2527752","article-title":"Nanomedicine initiates ferroptosis for enhanced lung cancer therapy","volume":"32","author":"Xu","year":"2025","journal-title":"Drug. Deliv."},{"key":"10.1016\/j.colsurfb.2026.116154_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.113869","article-title":"Emerging application of nanomedicine-based therapy in acute respiratory distress syndrome","volume":"237","author":"Xu","year":"2024","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2026.116154_bib40","article-title":"Nanomedicine strategies for disulfidptosis activation in SLC7A11-high tumors","volume":"257","author":"Ye","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"27","key":"10.1016\/j.colsurfb.2026.116154_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fphar.2018.00027","article-title":"Transporter-Guided Delivery of Nanoparticles to Improve Drug Permeation across Cellular Barriers and Drug Exposure to Selective Cell Types","volume":"9","author":"Kou","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.colsurfb.2026.116154_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.115237","article-title":"Targeting macrophage polarization with opsonized bilirubin\/melatonin nanoparticles: A biomimetic approach for acute lung injury","volume":"258","author":"Lou","year":"2026","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"27","key":"10.1016\/j.colsurfb.2026.116154_bib43","doi-asserted-by":"crossref","first-page":"30031","DOI":"10.1021\/acsami.0c03564","article-title":"Tumor Microenvironment-Responsive, Multistaged Liposome Induces Apoptosis and Ferroptosis by Amplifying Oxidative Stress for Enhanced Cancer Therapy","volume":"12","author":"Kou","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"11","key":"10.1016\/j.colsurfb.2026.116154_bib44","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3390\/antiox12111953","article-title":"The Key Role of GSH in Keeping the Redox Balance in Mammalian Cells: Mechanisms and Significance of GSH in Detoxification via Formation of Conjugates","volume":"12","author":"Georgiou-Siafis","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.colsurfb.2026.116154_bib45","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jconrel.2020.08.054","article-title":"Therapeutic application and construction of bilirubin incorporated nanoparticles","volume":"328","author":"Yao","year":"2020","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.colsurfb.2026.116154_bib46","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1021\/acsnano.2c06313","article-title":"A Ferroptosis-Inducing and Leukemic Cell-Targeting Drug Nanocarrier Formed by Redox-Responsive Cysteine Polymer for Acute Myeloid Leukemia Therapy","volume":"17","author":"Yu","year":"2023","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.116154_bib47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12951-024-02574-6","article-title":"Glutathione-depleting liposome adjuvant for augmenting the efficacy of a glutathione covalent inhibitor oridonin for acute myeloid leukemia therapy","volume":"22","author":"Liu","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"4","key":"10.1016\/j.colsurfb.2026.116154_bib48","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"\u03b3H2AX: a sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.colsurfb.2026.116154_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116663","article-title":"H2AX: A key player in DNA damage response and a promising target for cancer therapy","volume":"175","author":"Prabhu","year":"2024","journal-title":"Biomed. & Pharmacother."}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526007423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526007423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:51:16Z","timestamp":1789933876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776526007423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":49,"alternative-id":["S0927776526007423"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.116154","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCR4-directed liposomal co-delivery of cytarabine and AMD3100 for redox-associated chemosensitization in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.116154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116154"}}